GnRH ant

ApprovedSmall molecule

Merck & Co.

GnRH ant is one of 217 small molecule programs targeting Hyperplasia. It is currently in Approved.

Indications

Total Trials

Active Trials

216

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaActive, not recruiting

Female InfertilityActive, not recruiting

Uterine FibroidActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Polycystic Ovary SyndromeActive, not recruiting

Prostate CancerActive, not recruiting

Endometrial CancerActive, not recruiting

Ovarian Hyperstimulation SyndromeActive, not recruiting

HyperplasiaPhase 2/Phase 3

Active, not recruiting

Female InfertilityPhase 1/Phase 2

Active, not recruiting

Uterine FibroidApproved

Active, not recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

Polycystic Ovary SyndromePhase 3

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Endometrial CancerPhase 2/Phase 3

Active, not recruiting

Ovarian Hyperstimulation SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

GnRH ant

Merck & Co.

Approved

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Duragesic

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Statin

Bristol-Myers Squibb

Preclinical

1 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalNot yet recruiting

Ovarian Stimulation

NCT06396390

Q4 2026

Phase 2Not yet recruiting

Ovarian Stimulation

NCT06212102

Phase 3Recruiting

Blastocyst

NCT05447208

Q1 2027

Phase 2/3Recruiting

Endometrial Cancer

NCT06379113

Q3 2027

Phase 2/3Active, not recruiting

Hyperplasia

NCT06390904

Clinical

Trials by Indication[1]

GnRH Antagonist5 trials

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

Completed·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT04414748·400 enrolled

Preventive Application of GnRH Antagonist on Early OHSS

Unknown status·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT03188471·175 enrolled

Administration of GnRH Antagonist to Oocyte Donation Recipients

Completed·CCentro Ginecologia y Obstetricia.··NCT00635258·100 enrolled

Show 2 more trials

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

Completed·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT04414761·784 enrolled

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

Not yet recruiting·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT05326087·204 enrolled

Ovarian Stimulation3 trials

Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes

Not yet recruiting·NNesta Clinic·Phase 4·NCT06396390·152 enrolled

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Not yet recruiting·—·Phase 2·NCT06212102·120 enrolled

Random-start Ovarian Stimulation in Egg-donors (ROSE)

Terminated·IInstituto Bernabeu·Phase 4·NCT02821819·15 enrolled

Testosterone3 trials

Effects of Testosterone and Fat Utilization

Completed·UUniversity of Colorado, Denver·N/A·NCT03289559·13 enrolled

Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males

Completed·LLund University·N/A·NCT03541395·30 enrolled

The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

Not yet recruiting·UUniversity of British Columbia·N/A·NCT07212712·50 enrolled

Polycystic Ovary Syndrome2 trials

GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer

Completed·SSeoul National University Hospital·Phase 3·NCT01402336·43 enrolled

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

Terminated·YYale University·Phase 1·NCT04327934·28 enrolled

Controlled Ovarian Stimulation2 trials

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Completed·OOrganon and Co·Phase 3·NCT00696878·682 enrolled

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01079949·93 enrolled

28 more indications

Body Weight1 trial

The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles

Unknown status·—·N/A·NCT03457233·185 enrolled

Prostate Cancer1 trial

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Recruiting· Amgen logo

Amgen·Phase 1·NCT06613100·40 enrolled

Progesterone1 trial

Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.

Completed·FFundacion Dexeus·N/A·NCT04108039·44 enrolled

SMA1 trial

The Effect of ADT on PSMA-PET.

Unknown status·TTurku University Hospital·N/A·NCT03313726·30 enrolled

Polycystic Ovarian Syndrome1 trial

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

Completed·—··NCT06812559·100 enrolled

Metastatic Prostate Cancer1 trial

The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer

Unknown status·TTurku University Hospital·N/A·NCT03876912·35 enrolled

Ovarian Function1 trial

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

Withdrawn·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 4·NCT00507780

Endometrial Cancer1 trial

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Recruiting·XXiaojun Chen·Phase 2/3·NCT06379113·29 enrolled

CLE1 trial

Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles

Completed·—·Phase 4·NCT04008966·160 enrolled

Polycystic Ovarian Syndrome (PCOS)1 trial

A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation

Completed· Merck & Co. logo

Merck & Co.··NCT02607293·1,064 enrolled

Insulin Sensitivity1 trial

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00470990·40 enrolled

Phase II1 trial

Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol

Unknown status·—·N/A·NCT03484611·179 enrolled

Menopause1 trial

Bioenergetic Effects of Aging and Menopause (BEAM)

Unknown status·UUniversity of Colorado, Denver·Phase 4·NCT04043520·57 enrolled

Female Infertility1 trial

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

Completed·LLebanese University·Phase 1/2·NCT04071574·200 enrolled

Hyperplasia1 trial

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Active, not recruiting·XXiaojun Chen·Phase 2/3·NCT06390904·29 enrolled

Hemodynamic1 trial

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Active, not recruiting·UUniversity of Colorado, Denver·Phase 4·NCT05057546·55 enrolled

Steroid1 trial

Metabolic Effects of Steroids in Obese Men

Unknown status·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00983554·57 enrolled

Embryo Transfer1 trial

GnRH Antagonist to Prepare Recipients for Embryo Transfer

Completed·IInstitute for Human Reproduction (IHR)·N/A·NCT00460642·130 enrolled

In Vitro Fertilization (IVF)1 trial

Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

Completed·—·Phase 1·NCT02640976·216 enrolled

Embryo1 trial

DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore

Completed·IIVI Madrid·N/A·NCT03291821·136 enrolled

Pregnancy1 trial

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

Completed·OOrganon and Co··NCT00702234·268 enrolled

Diagnosis1 trial

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

Completed·UUniversitair Ziekenhuis Brussel·Phase 4·NCT01888744·120 enrolled

Blastocyst1 trial

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Recruiting·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT05447208·400 enrolled

Cohort Study1 trial

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Completed·SShangHai Ji Ai Genetics & IVF Institute·Phase 3·NCT05574894·692 enrolled

Ovarian Hyperstimulation Syndrome1 trial

GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

Completed·IInstituto Valenciano de Infertilidad, IVI VALENCIA·Phase 3·NCT01268761·100 enrolled

Uterine Fibroid1 trial

Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids

Completed·UUniversity of Edinburgh·Phase 4·NCT00746031·30 enrolled

Treatment1 trial

Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET

Unknown status·—·Phase 2·NCT04268927·106 enrolled

Unspecified1 trial

Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Completed·YYazd Research & Clinical Center for Infertility·Phase 4·NCT00830492·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 43 trial records for GnRH ant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH ant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH ant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

GnRH ant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

GnRH Antagonist5 trials

Ovarian Stimulation3 trials

Testosterone3 trials

Polycystic Ovary Syndrome2 trials

Controlled Ovarian Stimulation2 trials

Body Weight1 trial

Prostate Cancer1 trial

Progesterone1 trial

SMA1 trial

Polycystic Ovarian Syndrome1 trial

Metastatic Prostate Cancer1 trial

Ovarian Function1 trial

Endometrial Cancer1 trial

CLE1 trial

Polycystic Ovarian Syndrome (PCOS)1 trial

Insulin Sensitivity1 trial

Phase II1 trial

Menopause1 trial

Female Infertility1 trial

Hyperplasia1 trial

Hemodynamic1 trial

Steroid1 trial

Embryo Transfer1 trial

In Vitro Fertilization (IVF)1 trial

Embryo1 trial

Pregnancy1 trial

Diagnosis1 trial

Blastocyst1 trial

Cohort Study1 trial

Ovarian Hyperstimulation Syndrome1 trial

Uterine Fibroid1 trial

Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News